Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | GABRE | P78334 | 1/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27334869 | 0.83 | CYP2A6 (0.47) | CYP2A6ACACBLMNAGABRPGABRD | |
| SCHEMBL6446069 | 0.83 | MMP2 (0.55) | MMP2MMP12KDM4ELMNAGABRP | |
| SCHEMBL5050178 | 0.81 | CYP2A6 (0.64) | CYP2A6ACACBLMNALPLLIPG | |
| SCHEMBL8228398 | 0.81 | CYP2A6 (0.64) | CYP2A6ACACBLMNALPLLIPG | |
| SCHEMBL19021213 | 0.80 | FFAR1 (0.51) | KDM4ELMNALPLLIPGALDH1A1 | |
| SCHEMBL17954218 | 0.80 | CYP2A6 (0.52) | CYP2A6ACACBLPLLIPGALDH1A1 | |
| SCHEMBL9335788 | 0.80 | CYP2A6 (0.52) | CYP2A6ACACBGABRPGABRDGABRA1 | |
| SCHEMBL28847039 | 0.78 | CYP2A6 (0.50) | CYP2A6ACACBLPLLIPGALDH1A1 | |
| SCHEMBL7844489 | 0.78 | MMP2 (0.41) | MMP2MMP12ACACBKDM4ELMNA | |
| SCHEMBL15921211 | 0.77 | FFAR1 (0.56) | KDM4ELMNALPLLIPGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466790-B | Preparation method of alpha-sulfinylated carbonyl compound | 西北师范大学 | 2024-05-28 | — | — | CN | claimed |
| CN-117466790-A | Preparation method of alpha-sulfinylated carbonyl compound | 西北师范大学 | 2024-01-30 | — | — | CN | claimed |
| CN-117466790-B | Preparation method of alpha-sulfinylated carbonyl compound | 西北师范大学 | 2024-05-28 | — | — | CN | disclosed |
| CN-117466790-A | Preparation method of alpha-sulfinylated carbonyl compound | 西北师范大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-115806471-A | Preparation method for preparing substituted propargyl alcohol by catalyzing paraformaldehyde and alkyne with alkali | 延安大学 | 2023-03-17 | — | — | CN | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| WO-2007042660-A2 | SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-04-19 | — | — | WO | disclosed |
| US-4322432-A | Cyclopropanecarboxylic acid alkynyl esters, processes for producing them, and their use as pesticides | CIBA-GEIGY CORPORATION (US) | 1982-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | AGTR1, AGTR2, AHR | CYP2A6 816/4885MMP2 4136/4885MMP12 2988/4885 |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | CYP2A6 211/4885MMP2 4756/4885MMP12 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.